



Pines Education Institute of S.W. Florida

Meeting Title:

Forging Ahead For Optimal Management Of Multiple Myeloma

Presented by:

Deborah Doss RN, OCN
Dana-Farber Cancer Institute
Boston, Mass

Sponsored by
Medical Education Resources, Inc.
Supported by
an educational grant from **MILLENIUM**

LEARNING OBJECTIVES: the participant will be able to

- Discuss the therapies and combinations of agents currently used or under research to treat multiple myeloma
- List 2 side effects from multiple myeloma treatment that require immediate management
- Describe typical clinical presentation of multiple myeloma
- Discuss brief history of evolution of multiple myeloma treatment

This CE activity provides 1.0 contact hours for nurses.

To register for this seminar please contact:

JoAnn Westbrook, Director 941-365-0250 x 1114 or jwest@pinesofsarasota.org

Monday,
March 17, 2008
1:00 PM – 2:00 PM
Lunch will be served

Cost: **FREE**

Where: **Culler's Hall**

Pines of Sarasota
1501 N. Orange Ave.
Sarasota, FL 34236
941-365-0250

STATEMENT OF NEED:

Multiple myeloma (MM), a hematologic malignancy of plasma cells, is highly treatable but remains a "cancer without a cure", and most patients relapse at some point during their treatment. The American Cancer Society estimated that there would be 16,570 new cases of MM in 2007 with 11,310 deaths. Median survival is approximately 24 to 30 months and the 10 year survival rate is 3% or less. The former "gold standard" treatment for MM, melphalan (L-PAM) and prednisone was introduced more than 30 years ago. Since then, newer immunomodulatory agents and a proteasome inhibitor have been used in an attempt to treat the disease and overcome the multi-drug resistance (MDR) that is common among MM patients.

Because there are relatively few cases of MM per year and many of the patients are referred for transplant to larger academic centers, community practice oncology nurses may not be as familiar with either the disease or new treatment advances. In addition, the larger phase III trials for MM are generally conducted in academic institutions, and it becomes challenging for oncology nurses not directly involved in the trials to keep abreast of the latest data from these trials. The last decade has provided a number of new therapies and combinations of therapies that are prolonging and improving the quality of life of MM patients.

Pines of Sarasota is a charitable non-profit community dedicated to providing to adults with limited resources excellent care encompassing health, social, and support services and programs which enhance quality of life in a residential setting.

If not us, then who?